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SUPPLEMENTARY TABLE 1. PATHOGEN-ASSOCIATED MOLECULAR PATTERNS AND THEIR INNATE RECEPTORSPAMP Pathogen PRR Innate response
Microbial cell wall components,
eg peptidoglycan, teichoic acid
Streptococci, staphylococci Complement Opsonisation, complement activation














TLR2 Macrophage activation, secretion
of inﬂammatory cytokines
Double-stranded RNA Rotavirus and many other RNA
and DNA viruses






TLR4 Macrophage activation, secretion
of inﬂammatory cytokines
Flagellin from bacterial ﬂagella Pseudomonas species, E. coli TLR5 Macrophage activation, secretion
of inﬂammatory cytokines
Uracil-rich single-stranded RNA RNA viruses including HIV TLR7 Production of type 1 interferon
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SUPPLEMENTARY TABLE 2. CHEMOKINE RECEPTORS AND LIGANDS
Receptor Chemokine ligands Functional expression
CXCR1 CXCL2, 3, 5, 6, 7, 8 PMN, mast cells, monocytes, macrophages
CXCR2 CXCL1, 2, 3, 5, 6, 7, 8 PMN, mast cells, monocytes, macrophages
CXCR3 CXCL9, 10, 11 T cells (Th1 > Th2), B cells NK
CXCR4 CXCL12 T cells, B cells, PMN, monocytes, macrophages, DC
CXCR5 CXCL13 B cells, memory T cells
CXCR6 CXCL16 Memory T cells
CCR1 CCL3, 5, 7, 14, 15, 16, 23 Memory T cells, monocytes
CCR2 CCL2, 7, 12, 13 Monocytes
CCR3 CCL5, 7, 8, 13, 15, 24, 26 DC, NK, T cells, basophils, PMN
CCR4 CCL17, 22 Eosinophils, basophils, mast cells, T cells (Th2 > Th1)
CCR5 CCL3, 4, 5 T cells (Th2 > Th1)
CCR6 CCL20 Th1 cells, monocytes, macrophages, DC
CCR7 CCL19, 21 Memory T cells, DC
CCR8 CCL1, 4 T cells, B cells, DC
CCR9 CCL25 Th2 cells
CCR10 CCL27 Subsets of T cells, DC, macrophages
CCR11 CCL2, 8, 13 Subsets of T cells
CX3CR1 CX3CL1 PMN, monocytes, NK, T cells
XCR1 XCL1, XCL2 T cells
R, receptor (preceded by the chemokine motif); L, ligand (preceded by the chemokine motif); PMN, polymorphonuclear leukocytes;
Th, T helper; NK, natural killer cell; DC, dendritic cell.
SUPPLEMENTARY TABLE 1.dCONTINUED
PAMP Pathogen PRR Innate response
CpG motif-containing DNA Occur frequently in viral and
bacterial genomes
TLR9 Macrophage activation, secretion
of inﬂammatory cytokines
PAMP, pathogen-associated molecular patterns; PRR, pattern recognition receptor; TLR, Toll-like receptor; CpG, cytosine-phosphate-guanosine;
HIV, human immunodeﬁciency virus.
II UNDERSTANDING MODERN VACCINES
SUPPLEMENTARY TABLE 3. T-HELPER CELL SUBTYPES CAN BE CLASSIFIED BY THEIR CYTOKINE SECRETION
Subfamily Effector cytokines Targets Effects
Th1 IFNg Macrophages, DCs Immune responses against intracellular pathogens
Th2 IL-4, IL-13 Basophils, eosinophils, B cells Immune responses against extracellular pathogens
(parasites)
Th17 IL-17, IL-9, IL-22, IL-23 Neutrophils Inﬂammation, immune responses against extracellular
pathogens (parasites)
Tfh IL-21 B cells Class switching and afﬁnity maturation of antibody
Treg TGFb, IL-10 Other T-cell families Suppression/cessation of immune responses
Th, T helper; IFN, interferon; DC, dendritic cell; IL, interleukin; Tfh, follicular T helper; Treg, regulatory T cell; TGF, transforming growth factor.
Note: analysis of cloned Tcells suggests that individual cells rarely secrete a single cytokine, and it is the bias of the cytokine expression proﬁle
by the cell population, and relative levels of expression of different cytokines, that determine the nature of the subsequent immune response.
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SUPPLEMENTARY TABLE 5. KEY FUNCTIONS OF SELECTED CYTOKINES
Cytokine Phase Source Target/effects
IL-1 Innate Myeloid cells; epithelial/endothelial
cells
Inﬂammation, fever, cell activation
IL-2 Adaptive T cells Proliferation of T and B cells; activation of NK cells
and innate T cells
IL-4 Adaptive Th2 cells; mast cells Promotion of Th2 bias; class switching to IgE
IL-5 Adaptive Th2 cells Activation of eosinophils
IL-6 Innate Myeloid cells; epithelial/endothelial
cells; ﬁbroblasts
Inﬂammation; proliferation of B cells, promotion of
antibody secretion
IL-12 Innate Macrophages, DC Promotion of Th1 bias; activation of NK cells/innate T cells
IL-17: six isoforms,
all from different genes
Adaptive Subsets of Tcells; other leukocytes;
skeletal muscle; nervous tissue
Stimulation of inﬂammatory cytokines; angiogenesis;
affects endothelial and epithelial cells
IL-21 Innate and
adaptive
Subsets of T cells Regulation of NK cells and cytotoxic T cells; promotes cell
division/proliferation
TNFa Innate Myeloid cells Inﬂammation, fever, activation of neutrophils, apoptosis
IFNa Innate Plasmacytoid DC; ﬁbroblasts Promotes MHC I expression; activation of NK cells;
promotes CD8+ T cell response
IFNb Innate Fibroblasts Promotes MHC I expression; activation of NK cells
IFNg Adaptive Th1 cells; CD8+ T cells; NK cells;
innate T cells
Activation of macrophages/DC, promotes expression
of MHC II, promotes antigen presentation
TGFb Adaptive T cells; macrophages Inhibition of T cells, inhibition of B-cell proliferation, class
switching to IgA, inhibition of macrophages
IL, interleukin; NK, natural killer; Th, T helper; Ig, immunoglobulin; DC, dendritic cell; TNF, tumour necrosis factor; IFN, interferon; MHC, major
histocompatibility complex; CD, cluster of differentiation; TGF, transforming growth factor.
IV UNDERSTANDING MODERN VACCINES
SUPPLEMENTARY TABLE 6. A SUMMARY OF LICENSED VACCINES
Target Speciﬁc antigen(s) Vaccine type (all intramuscular unless noted)
Anthrax Bacillus anthracis protective antigen protein Subunit, aluminium salt adjuvant
Cholera Vibrio cholerae inactivated virus O1, cholera
toxin B subunit
Inactivated virus and protein subunit,
oral administration
Diphtheria e see DTwP/DTaP etc
Diphtheria, tetanus (DT) Diphtheria toxoid, tetanus toxoid Combination, aluminium salt adjuvant
Diphtheria, tetanus, pertussis
(DTwP)
Diphtheria toxoid, tetanus toxoid, whole-cell
pertussis
Combination subunit antigens with inactivated
whole-cell pertussis, aluminium salt adjuvant
Diphtheria, tetanus, pertussis,
hepatitis B (DTwP-HBV)
Diphtheria toxoid, tetanus toxoid, whole-cell
pertussis, recombinant hepatitis B surface
antigen (HBsAg)
Combination subunit antigens with inactivated
whole-cell pertussis, aluminium salt adjuvant
Diphtheria, tetanus, pertussis
(DTaP)
Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*




Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*
Combination subunit antigens, aluminium salt
adjuvant for booster dose
Diphtheria, tetanus, pertussis and
polio virus (DTaP-IPV)
Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*, inactivated polio virus
Combination subunit antigens, inactivated polio
virus, aluminium salt adjuvant
Diphtheria, tetanus, pertussis,
hepatitis B and polio virus
(DTaP-HBV-IPV)
Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*, recombinant hepatitis B
surface antigen (HBsAg), inactivated polio
virus
Combination subunit antigens, inactivated polio
virus, aluminium salt adjuvant
Diphtheria, tetanus, pertussis,
polio virus and Haemophilus
inﬂuenzae type b (DTaP-IPV-Hib)
Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*, inactivated polio virus,
Haemophilus inﬂuenzae type b
polysaccharide conjugated with tetanus or
modiﬁed diphtheria toxoids (CRM197)
Combination subunit antigens, inactivated polio
virus, aluminium salt adjuvant
Diptheria, tetanus, pertussis,
polio virus, hepatitis B and
Haemophilus inﬂuenzae type b
(DTaP-IPV-HBV-Hib)
Diphtheria toxoid, tetanus toxoid, acellular
pertussis antigens*, inactivated polio virus,
recombinant hepatitis B surface antigen
(HBsAg), Haemophilus inﬂuenzae type b
polysaccharide conjugated with tetanus or
modiﬁed diphtheria toxoids (CRM197)
Combination subunit antigens, inactivated polio
virus, aluminium salt adjuvant
ContinuedContinued on next page
APPENDICES V
SUPPLEMENTARY TABLE 6.dCONTINUED
Target Speciﬁc antigen(s) Vaccine type (all intramuscular unless noted)
Haemophilus inﬂuenzae type b
(Hib)
Haemophilus inﬂuenzae type b
polysaccharide conjugated with tetanus
or modiﬁed diphtheria toxoids (CRM197),
or outer membrane protein (OMP)
Subunit
Haemophilus inﬂuenzae type b
(Hib) and hepatitis B
Haemophilus inﬂuenzae type b
polysaccharide conjugated with tetanus or
modiﬁed diphtheria toxoids (CRM197), or
OMP and recombinant hepatitis B surface
antigen (HBsAg)
Subunit, aluminium salt adjuvant
Hepatitis A Inactivated hepatitis A virus Inactivated (whole cell), aluminium salt adjuvant
Hepatitis A Inactivated hepatitis A virus Inactivated (whole cell), virosome adjuvant
Hepatitis A and hepatitis B Inactivated hepatitis A virus, recombinant
hepatitis B surface antigen (HBsAg)
Inactivated and subunit (HBV), aluminium salt
adjuvant
Hepatitis B Recombinant hepatitis B surface antigen
(HBsAg)
Subunit, aluminium salt adjuvant
Hepatitis B Recombinant hepatitis B surface antigen
(HBsAg)
Subunit, AS04 adjuvant: aluminium salt and
monophosphoryl lipid A (MPL)
Human papillomavirus (HPV)
(cervical cancer and genital warts)
Quadrivalent, viral coat recombinant proteins
L1 from HPV types 16, 18, 6 and 11




Bivalent, viral coat recombinant proteins L1
from HPV types 16 and 18
Subunits as VLPs, AS04 adjuvant: aluminium salt
and monophosphoryl lipid A
Inﬂuenza e seasonal Trivalent, types A (H1N1, H3N2) and B
(speciﬁc antigen types vary each ﬂu season)
Inactivated (whole cell)
Inﬂuenza e seasonal Trivalent, types A (H1N1, H3N2) and B
(speciﬁc antigen types vary each ﬂu season)
fragmented viruses
Split and subunit available
Inﬂuenza e seasonal Trivalent, types A (H1N1, H3N2) and B
(speciﬁc antigen types vary each ﬂu season)
Ha and NA
Subunit, oil-in-water emulsion adjuvant (MF59)
Inﬂuenza e seasonal Trivalent, types A (H1N1, H3N2) and B
(speciﬁc antigen types vary each ﬂu season)
Ha and NA
Subunit, virosome adjuvant
Continued on next page
VI UNDERSTANDING MODERN VACCINES
SUPPLEMENTARY TABLE 6.dCONTINUED
Target Speciﬁc antigen(s) Vaccine type (all intramuscular unless noted)
Inﬂuenza e seasonal Trivalent, types A (H1N1,H3N2) and B
(speciﬁc antigen types vary each ﬂu season)
cold attenuated viruses
Live attenuated, for intranasal delivery
Inﬂuenza e pandemic H1N1 Inactivated whole cell
Inﬂuenza e pandemic H1N1 Subunit, oil-in-water emulsion adjuvant (MF59)
Inﬂuenza e pandemic H1N1 Split, AS03 Adjuvant System
Inﬂuenza e pandemic H1N1 Split, thermoreversible oil-in-water emulsion adjuvant
Inﬂuenza e pandemic H1N1 Live attenuated, for intranasal delivery
Inﬂuenza e pandemic H5N1 Split
Inﬂuenza e pandemic H5N1 Whole cell, aluminium salt adjuvant
Inﬂuenza e pandemic H5N1 Subunit, oil-in-water emulsion adjuvant (MF59)
Inﬂuenza e pandemic H5N1 Split, AS03 Adjuvant System
Japanese encephalitis (JE) Japanese encephalitis virus Inactivated (whole cell), aluminium adjuvant
Measles Measles virus Live attenuated, subcutaneous injection
Measles, mumps, rubella (MMR) Measles, mumps and rubella viruses Live attenuated, subcutaneous injection
Measles, mumps, rubella,
varicella (MMRV)
Measles, mumps, rubella and varicella
viruses
Live attenuated, subcutaneous injection
Meningococcus (Neisseria
meningitidis)
Meningococcal oligosaccharides, Groups A,





Meningococcal polysaccharides, Groups C,





as ACWY and AC
Subunit
Meningococcus and Hib Meningococcal polysaccharide Group C, Hib
polysaccharide conjugated with T
Subunit
Monkeypox (smallpox vaccine) Vaccinia virus Live attenuated
Mumps Mumps virus Live attenuated, subcutaneous injection
Pertussis (whooping cough) e
see DTP combination vaccines
Continued
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APPENDICES VII
SUPPLEMENTARY TABLE 6.dCONTINUED
Target Speciﬁc antigen(s) Vaccine type (all intramuscular unless noted)
Pneumococcal Puriﬁed capsular polysaccharides from 23
Streptococcus pneumoniae subtypes
Subunit
Pneumococcal Capsular polysaccharides from seven
S. pneumoniae subtypesconjugatedwithCRM
Subunit aluminium salt adjuvant
Pneumococcal Capsular polysaccharides from 10
S. pneumoniae subtypes conjugated with
protein D, T and diphtheria toxoid
Subunit aluminium salt adjuvant
Pneumococcal Capsular polysaccharides from 13
S. pneumoniae subtypes, conjugated
with CRM
Subunit aluminium salt adjuvant
Polio Polio virus Inactivated whole cells
Polio Polio virus Live attenuated, oral delivery
Rabies Rabies virus Live attenuated
Rotavirus Rotavirus Live attenuated, oral delivery
Rotavirus Human-bovine reassortants from ﬁve
rotavirus serotypes
Live attenuated, oral delivery
Rubella (German measles) e see
also MMR and MMRV
combination vaccines
Rubella virus Live attenuated, subcutaneous injection
Shingles (herpes zoster) Varicella-zoster virus Live attenuated, subcutaneous injection
Smallpox Vaccinia virus Live attenuated, subcutaneous injection
Tetanus e see also DTP
combination vaccines
Tetanus toxoid Subunit for booster use only
Tuberculosis (TB) MycobacteriumbovisbacillusCalmette-Guérin
(BCG) culture
Live attenuated, intradermal injection
Typhoid Salmonella typhi culture Live attenuated, oral delivery
Typhoid S. typhi cell surface Vi polysaccharide Subunit
Varicella (chickenpox) Varicella virus Live attenuated, subcutaneous injection
Yellow fever Yellow fever virus Live attenuated, subcutaneous injection
*Acellular pertussis combinations may contain 2, 3 or 5 proteins.
VIII UNDERSTANDING MODERN VACCINES
SUPPLEMENTARY TABLE 7. NEW CANDIDATE T-CELL VACCINES FOR MALARIA INCLUDING THE STAGE OF
CLINICAL PHASE DEVELOPMENT
Approach Vaccine name Comment Manufacturer
Early-stage development (Phase I)
Recombinant proteins MSP1-42 Adjuvanted with CpG/aluminium salt MVDB (Malaria Vaccine Development Branch)
Recombinant proteins AMA1-C1 Adjuvanted with CpG/aluminium salt MVDB
Recombinant proteins SERA Adjuvanted with aluminium salt Osaka University, Biken Foundation
Recombinant proteins AMA1/MSP-1 Adjuvanted with Montanide ISA 720 Wanxing Biopharmaceuticals Co, Malaria
Vaccine Initiative (MVI), WHO
Attenuated sporozoites PfSPZ Radiation Sanaria Inc
Transmission-blocking
vaccine
PfS25 Prevents infection in mosquito.




PvS25 Prevents infection in mosquito.
Adjuvanted with Montanide ISA51
Sanaria Inc
DNA vaccine PfCSP DNA plasmid expressing CS National Institute for Allergy and Infectious
Diseases (NIAID)
Mid-stage development (Phase II)
Recombinant proteins LSA1 Adjuvanted with AS01 Walter Reed Army Institute of Research
(WRAIR), GSK, MVI
Recombinant proteins LSA3 Adjuvanted with Montanide ISA 720/
aluminium salt
Institut Pasteur, European Malaria Vaccine
Initiative (EMVI)
Viral vector Ad35 CS Expressed in adenovirus type 35 WRAIR, Crucell, GSK
Viral vector ME-TRAP Expressed in fowlpox and MVA Oxford University, MVI, Wellcome Trust
Viral vector CS + LSA1 Expressed in fowlpox and MVA Oxford University, EMVI, Wellcome Trust
Viral vector Adenovirus 5
CS and AMA1
Expressed in adenovirus type 5 Naval Medical Research Center (NMRC)
Virosome CS and AMA1 Synthetic peptides Swiss Tropical Institute (STI), Pevion Biotech Ltd
Late-stage development (Phase III)
Virus-like particle RTS,S Adjuvanted with AS01 GSK, MVI, WRAIR
MSP1-42, merozoite surface protein 1 (42); AMA1-C1, atypical membrane antigen 1 (C1); PfCSP, Plasmodium falciparum circumsporozoite
protein; LSA1, liver stage antigen 1; WHO, World Health Organization; CS, circumsporozoite; ME-TRAP, multiple epitope-thrombospondin-
related adhesion protein; MVA, modiﬁed vaccinia Ankara; CpG, cytosine next to guanine in a DNA sequence linked by a phosphodiester
bond. Every effort has been made to verify the information in the table above, the list of information is not meant to be exhaustive but to give
an overview of the subject matter.
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